Vicore Pharma: Interim report July-September 2023
Stockholm, November 2, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drug molecules – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the third quarter 2023.
